Contest Trader

Don't miss the chance to cash-in prizes totaling

$10.000
Register here for the Ultimate demo trading competition

Gilead cleared to distribute Remdesivir to hospitals

Gilead cleared to distribute Remdesivir to hospitals

Remdesivir to go global starting October

As the race of finding a viable #COVID-19 vaccine intensifies, some pharma companies are one step ahead of others.

Gilead, the California-based company, announced that alongside its distributor, it had been cleared to sell Remdesivir directly to hospitals. The clearance came from the US Department of Health and Human Services (#HHS).

The drug will be branded as Veklury. Until the clearance, the distribution of Remdesivir was oversaw by the federal government, but "because the drug is no longer a scarce resource," the oversight is no longer required.

Gilead stated that it has real-time demand for Remdesivir in the States, and starting in October, it is prepared to meet the global orders.

Gilead's Remdesivir became one of the frontrunners after the results of three clinical trials showed the benefits of the drug. Also, trial data showed that it shortens the recovery time, allowing hospitals not to be overcrowded.

The news came a few months after the Food and Drugs Administration green-lit the potential #vaccine to be used in emergency cases only.

During pre-market trading, Gilead stock price went up 2.56%.

Read about other pharmaceutical companies and their efforts to develop a COVID-19 vaccine here!

Sources: thestreet.com, finance.yahoo.com


Esta información preparada por za.capex.com no es una oferta o solicitud con el propósito de comprar o vender ningún producto financiero referido en el presente o participar en una relación legal, ni un consejo o recomendación con respecto a tales productos financieros.

Esta información está preparada para su circulación general. No se refiere a ningún objetivo de inversión específico, situación financiera o necesidad particular de un receptor.

Debería evaluar independientemente cada producto financiero y considerar la idoneidad de dicho producto, teniendo en cuenta sus objetivos de inversión específicos, la situación financiera o las necesidades particulares, y consultar con un asesor financiero independiente si fuera necesario, antes de operar con los productos financieros mencionados en este documento.

Esta información no debe ser publicada, estar en circulación, reproducida o distribuida en su totalidad o en parte a ninguna persona sin el consentimiento previo por escrito de la Compañía.

El rendimiento pasado no es siempre indicativo de las probabilidades o del rendimiento futuro. Todos los puntos de vista y opiniones presentados son exclusivamente del autor y no representan necesariamente las de za.capex.com